Now showing items 1-2 of 2

    • Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2 

      Plotkin, Scott Randall; Merker, Vanessa; Halpin, Chris; Jennings, Dominique; McKenna, Michael John; Harris, Gordon J.; Barker, Frederick George (Ovid Technologies (Wolters Kluwer Health), 2012)
      Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up ...
    • Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma 

      Plotkin, Scott Randall; Halpin, Chris; Blakeley, Jaishri O.; Slattery, William H.; Welling, Duane Bradley; Chang, Susan M.; Loeffler, Jay Steven; Harris, Gordon J.; Sorensen, A; McKenna, Michael John; Barker, Frederick George (Springer Nature, 2009)
      Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there ...